Evidence map›Paper›PMID 38887487›Full record

ArticleOpen forum infectious diseases2024

Challenges to Implementing a Vaccine for Coccidioidomycosis.

Bridget M Barker, George R Thompson, Neil M Ampel

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bridget M BarkerDepartment of Biological Sciences, Northern Arizona University, Flagstaff, Arizona, USA.
George R ThompsonDepartment of Medical Microbiology and Immunology, University of California at Davis, Davis, California, USA.ORCID https://orcid.org/0000-0001-8518-5750
Neil M AmpelDepartments of Medicine and Immunobiology, University of Arizona, Tucson, Arizona, USA.ORCID https://orcid.org/0000-0003-2872-4396

Funding

Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for CoccidioidomycosisU19AI166058 · NIAID · NORTHERN ARIZONA UNIVERSITY · PI Bridget Marie Barker · 2022 to 2026
$12.1M
Virulence gene discovery in CoccidioidesU19AI166798 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Satya Dandekar · 2022 to 2026
$10.5M
Rational design of a novel rapid diagnostic tool for coccidioidomycosisR21AI166614 · NIAID · NORTHERN ARIZONA UNIVERSITY · PI BARKER, BRIDGET MARIE, CATANZARO, DONALD G · 2023 to 2024
$452k
NIAID NIH HHS R21 AI166614NIAID NIH HHS U19 AI166058NIAID NIH HHS U19 AI166798
6 · The paper itself

Abstract

A vaccine for coccidioidomycosis is likely to undergo trials in the near future. In this paper, we raise 4 questions that should be answered before its use and offer our solutions to these questions. These include defining the goals of vaccination, determining who should be vaccinated, how to measure vaccine immunity and protection, and how to address vaccine hesitancy and denial.

Indexed as

coccidioidomycosisimmunizationmycosesvaccination

Identifiers

PMID38887487
PMCPMC11181188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.